Calidi Biotherapeutics
CLDI
30 hedge funds and large institutions have $1.53M invested in Calidi Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
30% more funds holding
Funds holding: 23 → 30 (+7)
0.02% more ownership
Funds ownership: 0.05% → 0.06% (+0.02%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
46% less capital invested
Capital invested by funds: $2.85M → $1.53M (-$1.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RWI
Red Wave Investments
Dillsburg,
Pennsylvania
|
+$501K |
| 2 |
AMH
Apollo Management Holdings
New York
|
+$106K |
| 3 |
CI
CPR Investments
Rochester,
Michigan
|
+$59.5K |
| 4 |
EWM
Evermay Wealth Management
Arlington,
Virginia
|
+$53.9K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$52.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$154K |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
-$56.3K |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$33.2K |
| 4 |
Renaissance Technologies
New York
|
-$26K |
| 5 |
AWM
Axxcess Wealth Management
Carlsbad,
California
|
-$19.9K |
CLDI Hedge Fund Activity: Q1 2024 in Review
30 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2024, worth a combined $1.53M — down 46% from $2.85M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLDI positions and 3 closed out — a net gain of 7 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Red Wave Investments, adding an estimated $501K. The largest seller was Millennium Management, exiting entirely with an estimated $154K sold.
- 30 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2024, up from 23 in Q4 2023.
- Funds reported $1.53M of Calidi Biotherapeutics stock for Q1 2024, down 46% quarter-over-quarter.
- 10 funds opened new Calidi Biotherapeutics positions in Q1 2024 and 3 closed out, a net change of +7 holders.
- The largest Calidi Biotherapeutics buyer in Q1 2024 was Red Wave Investments, an estimated $501K added.
- The largest Calidi Biotherapeutics seller in Q1 2024 was Millennium Management, an estimated $154K sold.
Based on aggregated 13F filings for Q1 2024.